EUVIMEDEUVIMED entdecken
Open Access

Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD

Jennifer W Leiding iD, Danielle E Arnold iD, Suhag Parikh iD, Brent Logan, Rebecca A Marsh, Linda M Griffith, Ruizhe Wu, Sharon Kidd, Kanwaldeep Mallhi, Deepak Chellapandian iD, Stephanie J Si Lim iD, Eyal Grunebaum und 48 weitere

Blood · 2023

DOI: 10.1182/blood.2022019586 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood, 2023. Verfasst von Jennifer W Leiding und 59 weiteren Autor:innen. Beteiligte Einrichtung: Division of Allergy and Immunology, Department of Pediatrics, Johns Hopkins University, Baltimore, MD. Hauptthemen laut MEDLINE: Granulomatous Disease, Chronic, Hematopoietic Stem Cell Transplantation, Graft vs Host Disease. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NCI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic granulomatous disease (CGD) is a primary immunodeficiency characterized by life-threatening infections and inflammatory conditions. Hematopoietic cell transplantation (HCT) is the definitive treatment for CGD, but questions remain regarding patient selection and impact of active disease on transplant outcomes. We performed a multi-institutional retrospective and prospective study of 391 patients with CGD treated either conventionally (non-HCT) enrolled from 2004 to 2018 or with HCT from 1996 to 2018. Median follow-up after HCT was 3.7 years with a 3-year overall survival of 82% and event-free survival of 69%. In a multivariate analysis, a Lansky/Karnofsky score <90 and use of HLA-mismatched donors negatively affected survival. Age, genotype, and oxidase status did not affect outcomes. Before HCT, patients had higher infection density, higher frequency of noninfectious lung and liver diseases, and more steroid use than conventionally treated patients; however, these issues did not adversely affect HCT survival. Presence of pre-HCT inflammatory conditions was associated with chronic graft-versus-host disease. Graft failure or receipt of a second HCT occurred in 17.6% of the patients and was associated with melphalan-based conditioning and/or early mixed chimerism. At 3 to 5 years after HCT, patients had improved growth and nutrition, resolved infections and inflammatory disease, and lower rates of antimicrobial prophylaxis or corticosteroid use compared with both their baseline and those of conventionally treated patients. HCT leads to durable resolution of CGD symptoms and lowers the burden of the disease. Patients with active infection or inflammation are candidates for transplants; HCT should be considered before the development of comorbidities that could affect performance status. This trial was registered at www.clinicaltrials.gov as #NCT02082353.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Granulomatous Disease, ChronicHematopoietic Stem Cell TransplantationGraft vs Host DiseaseHumansRetrospective StudiesProspective StudiesTransplantation, HomologousGenotypeTransplantation Conditioning

Autor:innen und Institutionen

  • Division of Allergy and Immunology, Department of Pediatrics, Johns Hopkins University, Baltimore, MD.
  • Institute for Clinical and Translational Research, Johns Hopkins All Children's Hospital, St. Petersburg, FL.
  • National Cancer Institute, National Institutes of Health, Bethesda, MD.
  • Aflac Cancer and Blood Disorders Center, Emory University and Children's Healthcare of Atlanta, Atlanta, GA.
  • Division of Biostatistics, Medical College of Wisconsin, Milwaukee, WI.
  • Division of Bone Marrow Transplantation and Immune Deficiency, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH.

ORCID-Profile: Jennifer W Leiding, Danielle E Arnold, Suhag Parikh, Deepak Chellapandian, Stephanie J Si Lim, Luis Murguia-Favela, Vinod K Prasad, Fabien Touzot, Jeffrey J Bednarski, Geoffrey D E Cuvelier, Lisa R Forbes Satter, Caridad Martinez, Susan E Prockop, Blachy J Dávila Saldaña, Larisa A Broglie, Christen L Ebens, Jordan Milner, Hemalatha G Rangarajan, Sharat Chandra, Morna J Dorsey, Morton J Cowan, Christopher C Dvorak

Förderung

  • NCATS NIH HHS
  • NCI NIH HHS
  • NIAID NIH HHS
  • NHLBI NIH HHS
  • NINDS NIH HHS
  • Intramural NIH HHS

Zitieren

APA

Leiding, J. W., Arnold, D. E., Parikh, S., Logan, B., Marsh, R. A., Griffith, L. M., Wu, R., Kidd, S., Mallhi, K., Chellapandian, D., Si Lim, S. J., Grunebaum, E., Falcone, E. L., Murguia-Favela, L., Grossman, D., Prasad, V. K., Heimall, J. R., Touzot, F., Burroughs, L. M., …, & Dvorak, C. C. (2023). Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD. Blood. https://doi.org/10.1182/blood.2022019586

Vancouver

Leiding JW, Arnold DE, Parikh S, Logan B, Marsh RA, Griffith LM, et al. Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD. Blood. 2023. doi:10.1182/blood.2022019586

BibTeX
@article{Leiding2023,
  author = {Leiding, Jennifer W and Arnold, Danielle E and Parikh, Suhag and Logan, Brent and Marsh, Rebecca A and Griffith, Linda M and Wu, Ruizhe and Kidd, Sharon and Mallhi, Kanwaldeep and Chellapandian, Deepak and Si Lim, Stephanie J and Grunebaum, Eyal and Falcone, E Liana and Murguia-Favela, Luis and Grossman, Debbi and Prasad, Vinod K and Heimall, Jennifer R and Touzot, Fabien and Burroughs, Lauri M and Bleesing, Jack and Kapoor, Neena and Dara, Jasmeen and Williams, Olatundun and Kapadia, Malika and Oshrine, Benjamin R and Bednarski, Jeffrey J and Rayes, Ahmad and Chong, Hey and Cuvelier, Geoffrey D E and Forbes Satter, Lisa R and Martinez, Caridad and Vander Lugt, Mark T and Yu, Lolie C and Chandrakasan, Shanmuganathan and Joshi, Avni and Prockop, Susan E and Dávila Saldaña, Blachy J and Aquino, Victor and Broglie, Larisa A and Ebens, Christen L and Madden, Lisa M and DeSantes, Kenneth and Milner, Jordan and Rangarajan, Hemalatha G and Shah, Ami J and Gillio, Alfred P and Knutsen, Alan P and Miller, Holly K and Moore, Theodore B and Graham, Pamela and Bauchat, Andrea and Bunin, Nancy J and Teira, Pierre and Petrovic, Aleksandra and Chandra, Sharat and Abdel-Azim, Hisham and Dorsey, Morna J and Birbrayer, Olga and Cowan, Morton J and Dvorak, Christopher C},
  title = {Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD},
  journal = {Blood},
  year = {2023},
  doi = {10.1182/blood.2022019586}
}
Kostenlos starten →